— Know what they know.
Not Investment Advice
Also trades as: 002399.SZ (SHZ) · $vol 9M · 9989.HK (HKSE) · $vol 0M

SHEZF OTC

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: +0.0% 1Y: +0.0% 3Y: -34.8% 5Y: -67.8%
$0.47
+0.00 (+0.00%)
 
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 49 · $689.0M mcap · 411M float · 0.0000% daily turnover

Cash Flow Trends

Operating Cash Flow
$2.2B +451.0% ▲
Capital Expenditures
$203M +54.4% ▲
5Y CAGR: -10.9%
Free Cash Flow
$2.0B +4367.6% ▲
Dividends Paid
$160M +62.5% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$344M -177.1% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
— Operating Activities —
Net Income$1.0B$233M$715M-$802M$625M
Depreciation & Amort.$304M$303M$308M$374M$331M
Stock-Based Comp.$319K$191K$0$0$0
Change in Working Capital-$765M-$1.1B-$2.3B-$801M$1.2B
Other Non-Cash Items-$523M$582M$532M$1.6B$35M
Operating Cash Flow$37M-$7M-$757M$398M$2.2B
— Investing Activities —
Capital Expenditures-$212M-$194M-$222M-$445M-$203M
Acquisitions (Net)$220K$2M$3M$0$0
Investment Purchases-$1.8B-$2.4B-$4.5B-$677M-$2.2B
Investment Sales$1.0B$3.3B$4.2B$1.6B$2.1B
Other Investing-$1.2B-$23M$742M$696M-$162M
Investing Cash Flow-$2.2B$720M$250M$1.2B-$415M
— Financing Activities —
Net Debt Issuance-$714M-$73M$594M-$882M-$2.0B
Stock Repurchased$0$0$0$0$0
Dividends Paid-$224M-$220M-$51M-$426M-$160M
Other Financing$3.7B-$16M-$14M$98M-$13M
Financing Cash Flow$2.5B-$501M$330M-$1.2B-$2.1B
Net Change in Cash$254M$149M-$160M$446M-$344M
Cash End of Period$1.3B$1.5B$1.3B$1.8B$1.4B
Free Cash Flow-$175M-$200M-$979M-$47M$2.0B

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms